JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, D.
Right arrow Articles by Juliano, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, D.
Right arrow Articles by Juliano, R. L.

Vol. 302, Issue 3, 963-971, September 2002

Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator

Dong Xu, Dongjiu Ye, Michael Fisher and R. L. Juliano

Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina

Selective inhibition of the multidrug resistance 1 (MDR1) gene and its product, the P-glycoprotein, a membrane transporter responsible for multidrug resistance, could be an important approach for enhancing cancer therapeutics. An emerging strategy for selective gene regulation involves designed zinc finger proteins that can recognize specific sequences in the promoter regions of disease-related genes. Herein, we investigate the behavior of clones of multidrug-resistant NCI/ADR-RES breast carcinoma cells displaying ponasterone-inducible expression of a designed transcriptional repressor targeted to the MDR1 promoter. The controlled production of this novel repressor resulted in major reductions in P-glycoprotein levels in these otherwise highly drug-resistant tumor cells. The regulated reduction of MDR1 expression in NCI/ADR-RES cells was accompanied by a marked increase in the rate of uptake of the P-glycoprotein substrate rhodamine 123. In addition, the cytotoxicity profile of the antitumor drug doxorubicin was dramatically altered in the induced cells compared with controls. The expression levels of other genes were examined both by a DNA array analysis of approximately 2000 genes and by biochemical techniques. Although some changes were observed in mRNA levels of nontargeted genes, the most dramatic effect by far was on MDR1, indicating that the action of the designed transcriptional repressor was quite selective. This study suggests that designed transcriptional regulators can be used to strongly and selectively influence expression of cancer-related genes, even under circumstances of extensive amplification of the target gene.

0022-3565/02/3023-0963$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
V. Dixit and R. L. Juliano
Selective Killing of Smad4-Negative Tumor Cells via a Designed Repressor Strategy
Mol. Pharmacol., July 1, 2008; 74(1): 289 - 297.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
R. L. Juliano, V. R. Dixit, H. Kang, T. Y. Kim, Y. Miyamoto, and D. Xu
Epigenetic manipulation of gene expression: a toolkit for cell biologists
J. Cell Biol., June 20, 2005; 169(6): 847 - 857.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Graslund, X. Li, L. Magnenat, M. Popkov, and C. F. Barbas III
Exploring Strategies for the Design of Artificial Transcription Factors: TARGETING SITES PROXIMAL TO KNOWN REGULATORY REGIONS FOR THE INDUCTION OF {gamma}-GLOBIN EXPRESSION AND THE TREATMENT OF SICKLE CELL DISEASE
J. Biol. Chem., February 4, 2005; 280(5): 3707 - 3714.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P. Blancafort, D. J. Segal, and C. F. Barbas III
Designing Transcription Factor Architectures for Drug Discovery
Mol. Pharmacol., December 1, 2004; 66(6): 1361 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Xu, H. Kang, M. Fisher, and R. L. Juliano
Strategies for Inhibition of MDR1 Gene Expression
Mol. Pharmacol., August 1, 2004; 66(2): 268 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Xu, D. Falke, and R. L. Juliano
P53-Dependent Cell-Killing by Selective Repression of Thymidine Kinase and Reduced Prodrug Activation
Mol. Pharmacol., August 1, 2003; 64(2): 289 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Wu, W. N. Hait, and J.-M. Yang
Small Interfering RNA-induced Suppression of MDR1 (P-Glycoprotein) Restores Sensitivity to Multidrug-resistant Cancer Cells
Cancer Res., April 1, 2003; 63(7): 1515 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
D. Falke, M. Fisher, D. Ye, and R. L. Juliano
Design of artificial transcription factors to selectively regulate the pro-apoptotic bax gene
Nucleic Acids Res., February 1, 2003; 31(3): e10 - e10.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.